• Effects of liraglutide in the treatment of obesity : a randomised, double-blind, placebo-controlled study
The frequency of obesity has risen dramatically in recent years but only few safe and eff ective drugs are currently available. We assessed the eff ect of liraglutide on bodyweight and tolerability in obese individuals without type 2 diabetes.

  • Effect of Human Chorionic Gonadotrophin on weight loss , hunger , and feeling of well being.
Since Simeons introduced his method of treating Obesity using HCG , there has been continuing controversy concerning the effect of HCG on the program….

  • Controversies in Plastic Surgery : Suction-Assisted Lipectomy (SAL) and the Hcg ( Human Chorionic Gonadotrophin ) protocol for Obesity treatment.
The advent of SAL has dramatically increased the number of obese patients coming to the clinics ……………
The HCG method for Obesity treatment appears to be complete program for the management of Obesity …

  • Association Between Estrogen Receptor α Gene Variation and Cardiovascular Disease
ATHEROTHROMBOTIC Cardiovascular diseases (CVDs) such as myocardial infarction (MI) and stroke are multifactorial disorders with substantial heritable components. Genetic constitution may contribute to underlying risk factors such as hypertension, diabetes mellitus, and hypercholesterolemia and also may act through other, unidentified routes to alter susceptibility to CVDevents.
  • Fracture Incidence in Relation to the Pattern of Use of Hormone Therapy in post menopausal women.
POSTMENOPAUSAL WOMEN WHO use hormone therapy are known to have a reduced incidence of fracture compared with women who do not. However, there is limited information on how long this protective effect persists after use ceases, how different types of hormones affect the risk of fracture, and how hormone therapy affects the risk of fracture of different bones.

  • Hormones, Brain and Stress
The stress system orchestrates body and brain responses to the environment. This action exerted by the mediators of the stress system has two modes of operation. The immediate response mode driven by corticotropin-releasing hormone (CRH) organises via CRH-1 receptors the behavioural, sympathetic and hypothalamic-pituitary-adrenal (HPA) responses to a stressor.

  • Zonisamide for Weight Loss in Obese Adults
THE PREVALENCE OF OBESITY HAS increased dramatically in the past decade in the United States and many other developed countries. Because obesity is associated with a significantly increased risk for type 2 diabetes, coronary heart disease, hypertension, numerous other major illnesses, and overall mortality from all causes, weight reduction is critical for the obese patient.

  • Androgenic Hormones Modulate Autoantibody Responses and Improve Survival in Murine Lupus
Antibodies to native DNA and to polyadenylic acid (Poly A) occur spontaneously and undergo a regulated switch from IgM to IgG during the course of autoimmune disease in NZB / NZW F1(B/W) mice. B/W females have higher titers and earlier
commitment to 7S antibodies to DNA and Poly A, whereas B/W males bind DNA and Poly A primarily by 19S antibodies. We have performed castration experiments to determine the effects of sex hormones on this switch from IgM to IgG

  • Bone Mineral Density Response to Estrogen Replacement in Frail Elderly Women
THE HIGHEST INCIDENCE OF osteoporotic fractures is in women older than 75 years, who constitute a rapidly expanding segment of the US population. Bone mineral density (BMD), which is a strong risk factor for osteoporosis, continues to decline with age. Indeed, recent prospective studies indicate that bone loss not only continues from middle age into old age but may in fact accelerate in elderly persons. Given the progressive increase in physical frailty that typically occurs in elderly women, an osteoporotic fracture, particularly of the hip, often contributes to the loss of functional independence.

  • Effect of Soy Protein Containing Isoflavones on Cognitive Function, Bone Mineral Density, and Plasma Lipids in Postmenopausal Women
THE SUDDEN DECLINE IN ESTROGEN levels after menopause coincides with acceleration of several aging processes.1Onaverage, bone mineral density (BMD) decreases and cognitive function declines, whereas total cholesterol and low-density lipoprotein cholesterol (LDL-C) increase. It has been suggested that postmenopausal estrogen therapy might counteract some of these changes. However, short-term estrogen use is associated with the recurrence of vaginal bleeding, 2 and longterm use has been associated with an increased risk of breast cancer,
stroke, and cardiovascular disease.

  • Effects Of Thyroxine As Compared With Thyroxine Plus Triiodothyronine In Patients With Hypothyroidism.
Patients with hypothyroidism are usually treated with thyroxine (levothyroxine) only, although both thyroxine and triiodothyronine are secreted by the normal thyroid gland. Whether thyroid secretion of triiodothyronine is physiologically important is unknown.

  • Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy
ESTROGEN THERAPY has been available to postmenopausal women for more than 60 years. Proven benefits include relief of vasomotor symptoms and vaginal atrophy and prevention and treatment of osteoporosis. Observational studies primarily examining unopposed estrogen preparations have suggested a 30% to 50% reduction in coronary events

  • Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy
THE HEART AND ESTROGEN/ progestin Replacement Study (HERS) was a randomized, blinded trial to determine the
effects of estrogen plus progestin compared with placebo in older postmenopausal women with coronary disease

  • Prescribing Hormone Replacement Therapy for Menopausal Symptoms
Menopause, the permanent cessation of menstruation after loss of ovarian follicular function, is clinically defined as the absence of menses for 12 months. Natural menopause occurs at an average age of 51 years; this age has remained constant since it was first recorded in 600 A.D. Approximately 1% of women become postmenopausal before 40 years of age, and 5% become postmenopausal after 55 years of age



Home | About AMARAims and Objectives | Membership | Upcoming Events | Past Events | Contact Us

Disclaimer | Privacy Policy | Terms & Conditions | Refund Policy

Copyright 2009 - 2015 Antiaging Medicine And Research. All Rights Reserved.